SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB: ADMP), today announced the technology which constitutes its compound APC-100 received a Notice of Allowance for its patent application in Canada. Broad claims to a patent entitled “Chroman-Derived Anti-Androgens for Treatment of Androgen-Mediated Disorders” have been allowed. These include claims for the use of APC-100 to treat prostate cancer and for the use of APC-100 to prevent the occurrence or recurrence of prostate cancer. Notice of Allowance is the final step in the issuance of a patent. This patent will significantly strengthen Adamis’ patent portfolio for the use of APC-100 in the treatment of prostate cancer.
